Beijing Shumande Pharmaceutical Implements Electronic Contract System (eSign)

I. Beijing Shumande Pharmaceutical Technology Development Co., Ltd.: A Digital Pioneer in Pharmaceutical Science

As a leading enterprise in China’s pharmaceutical science and technology sector, Beijing Shumande Pharmaceutical Technology Development Co., Ltd. (hereinafter referred to as “Shumande Pharmaceutical”) is committed to innovative drug research and development, clinical trials, and market promotion. Guided by the core values of “Science-Driven Medicine, Quality First, and Sincere Service,” the company continuously enhances its core competitiveness through technological innovation and management optimization. Facing intensified market competition and rising consumer demands for drug quality, Shumande Pharmaceutical recognized that traditional paper-based contract management could no longer meet business needs. To achieve digital transformation in contract management and improve operational efficiency and quality control, the company adopted the advanced Electronic Contract System (eSign), launching a new era of digital contract management.

II. Urgent Need for Digital Transformation in Contract Management

Under the traditional model, Shumande Pharmaceutical encountered critical challenges:

• Manual errors: Contract records relied on paper-based manual entries, leading to inaccuracies and difficulties in quick retrieval/analysis.
• Inefficient workflows: Cross-departmental collaboration was fragmented, delaying contract approvals and execution.
• Non-compliant 变更管理: Poor version control of contracts posed risks of outdated document usage, threatening drug quality.
• To address these issues, Shumande Pharmaceutical introduced the Singardi eSign system, leveraging digitalization to enhance contract management efficiency and transparency. The system integrates contract workflows, enabling real-time data sharing and collaborative management. Through data collection and analysis, eSign monitors contract statuses in real time, optimizes processes, reduces operational costs, and drives comprehensive organizational transformation.

III. eSign Project: Phased Implementation for Steady Digital Transformation

(A) Overall Planning Blueprint

Shumande Pharmaceutical adopted a “holistic planning, phased implementation” strategy for the eSign project:

1. Phase 1: System Planning and Infrastructure SetupThe project team studied global digital best practices and tailored a detailed plan aligned with Shumande’s needs. Key milestones included establishing eSign infrastructure and connecting contract management devices to the system, laying the foundation for full-scale adoption.
2. Phase 2: Core Module Deployment and OptimizationFocus areas included:Real-time data capture: Automated integration with lab and testing equipment reduced manual errors.Automatic record generation: eSign generated standardized records (e.g., inspection batches, material sources, test parameters) and supported export/print for audits.Data analytics: Real-time contract reports enabled proactive issue detection and multi-dimensional decision-making.Process optimizations cut waiting times and resource waste.
3. Phase 3: Full Integration and Deep ApplicationeSign integrated seamlessly with existing systems (e.g., ERP), breaking data silos and enabling end-to-end traceability. Advanced analytics provided actionable insights for management, ensuring transparent and compliant operations.

(B) Innovative Core Business Model

The eSign project revolved around three pillars:

• Contract Data Capture: Real-time data transfer from lab/testing equipment ensured accuracy and consistency.
• Automated Record Generation: Standardized records covered critical details (e.g., test batches, results) for audit trails.
• Data Analytics: Customizable dashboards and reports empowered proactive risk management and strategic planning.

(C) Robust Technical Architecture

Built on a scalable digital platform, eSign features:

• Distributed architecture: Optimized data storage/access for rapid query responses.
• High customization: Configurable workflows adapted to Shumande’s unique needs.
• Third-party integration: Seamless connectivity with ERP and other systems enabled cross-functional collaboration.

IV. Remarkable Outcomes: Comprehensive Improvement in Contract Management

(A) Internal Transformations

• Operational Efficiency:50% reduction in data capture time.80% faster record generation.60% shorter contract management cycles.
• Data Quality:100% consistency and accuracy through centralized data governance.Eliminated decision-making errors from fragmented data.
• Paperless Operations:Reduced document storage costs and environmental impact.Enhanced data security and auditability.

(B) Industry Impact and Social Value

• Industry Benchmark: Shumande’s success demonstrated eSign’s potential in pharmaceutical contract management, inspiring peers to embrace digitalization.
• Cost Savings: Reduced labor and administrative costs allowed reinvestment in R&D and innovation, strengthening competitiveness.

V. Future Outlook: Sustaining Innovation to Lead Industry

While eSign has laid a solid foundation, Shumande Pharmaceutical recognizes digital transformation as an ongoing journey:

• System Optimization: Enhance predictive analytics for risk 预警 and streamline contract retrieval.
• Advanced Analytics: Integrate AI/ML to uncover actionable insights from contract data.
• Ecosystem Integration: Explore connectivity with ERP and IoT systems for end-to-end supply chain optimization.
• By driving these initiatives, Shumande aims to pioneer smart, efficient operations, setting new standards for the pharmaceutical industry’s digital evolution.

VI. Related Solutions

1. Electronic Contract System (eSign)
2. GMP-Compliant Digital Quality Management Solution (QMS)

VII. Case References

1. Dingkang Biotech eSign Project
2. Taihe Tai eSign Project